Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04977050 · ClinicalTrials.gov registry record · NA

The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners

A NA study, sponsored by University of New Mexico.

Completed
Registry status
NA
Development phase
230
Enrollment target

NCT04977050: Completed NA study, sponsored by University of New Mexico.

NCT04977050 is a NA study that has completed, run by University of New Mexico. The registered enrollment target is 230 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04977050, a NA study, has completed, sponsored by University of New Mexico.

COMPLETED
Registry status
NA
Development phase
230 participants
Enrollment target

Study Summary

The long-term goal of the study is to mitigate the spread of the pandemic in miners, a population of high-risk, rural essential workers who are susceptible and vulnerable to COVID-19, partly based on exposure to particulate air pollution, and who are predominantly racial/ethnic minorities in New Mexico (NM) (3, 11). The study objective is to provide proof-of-principle for frequent point-of-care molecular testing as a workplace surveillance tool to monitor and prevent the spread of SARS-CoV-2 infection in this unique population. The central hypothesis is that frequent workplace molecular surveillance is an effective method to reduce SARS-CoV-2 infection and discover novel host risk factors for the virus. The site of molecular surveillance (intervention site) will be a surface coal mine in McKinley County, NM, located just outside the Eastern Agency of the Navajo Nation, comprised of 66% minority miners. This site offers a unique opportunity for a community-based study of SARS-CoV-2 infection in this population. Miners at the intervention site will provide nasal swabs before beginning their work shift on alternate days that will be analyzed with a 'screening' molecular test (12). This test is ideal because it is low cost, simple, portable, point-of-care, rapid, and can be performed by minimally trained professionals in low-infrastructure settings. The control site is a similar coal mine in Campbell County, Wyoming (WY). Both mines, operated by the same company, have similar engineering, administrative, and personal protective measures in place. The rationale for this study is to establish the suitability of longitudinal molecular surveillance to prevent and control SARS-CoV-2 infection in this unique population by completing the following specific aims.

Primary Outcome

Rapid antigen test for COVID-19

Interventions

  • DIAGNOSTIC_TEST Quidel quickvue antigen test for COVID-19

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2021-02-22
Est. Completion 2022-10-31
Phase NA
University of New Mexico

168 total trials

What the finished NCT04977050 record still lists

NCT04977050 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 1 intervention - of which Quidel quickvue antigen test for COVID-19 is the first listed.

NCT04977050 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04977050 about?

NCT04977050 is a clinical study titled "The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners". The long-term goal of the study is to mitigate the spread of the pandemic in miners, a population of high-risk, rural essential workers who are susceptible and vulnerable to COVID-19, partly based on exposure to particulate air pollution, and who are predominantly racial/ethnic minorities in New Mex...

What is the current status of trial NCT04977050?

This trial is currently completed. It is a NA study. The enrollment target is 230 participants. The study started on 2021-02-22. Estimated completion is 2022-10-31.

What interventions are being tested in trial NCT04977050?

The interventions under investigation include: Quidel quickvue antigen test for COVID-19 (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04977050?

This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04977050's enrollment target sits among peer trials

230 465th of 2000 higher than 1,533 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04977050, the US trial registry maintained by the National Library of Medicine. NCT04977050 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.